Biomedical Engineering Reference
In-Depth Information
20
LiposomalpH-SensitiveNanomedicines
in
Preclini
calDevelopment
MariaJoseMorillaandEderLiliaRomero
ProgramadeNanomedicinas,UniversidadNacionaldeQuilmes,BuenosAires,Argentina
CONTENTS
20.1. Introduction:.Nanomedicines.Are.the.Key.to.Intracellular.Targeting..................... 384
20.2. DOPE-Containing.Liposomes:.Acid.Triggering.the.Lα.→.H
II
.Phase.Transition.... 386
20.2.1. Plasma.Stability.................................................................................................. 387
20.2.2. Pharmacokinetics.and.Biodistribution............................................................ 390
20.3. Tunable.pH-Sensitive.Liposomes:.Plasma-Stable.Liposomes.................................... 391
20.4. DOPE.pH-Sensitive.Liposomes.+.Cleavable.Peg......................................................... 392
20.5. Liposomes.Made.of.Hydrolyzable.Lipids..................................................................... 394
20.6. Liposomes.Bearing.pH-Sensitive.Polymers.................................................................. 395
20.6.1. Liposomes.Bearing.NIPA.Polymers................................................................. 395
20.6.2. Liposomes.Bearing.Polyphosphazenes:.Speed.of.Release........................... 397
20.6.3. Liposomes.Bearing.Polyglycidols.................................................................... 397
20.7. Preclinal.Applications.of.Pegylated.pH-Sensitive.Liposomes................................... 399
20.7.1. Tumor.Therapy/Cisplatin.................................................................................. 399
20.7.2. Tumor.Therapy/Gemcitabine........................................................................... 399
20.7.3. Scintigraphic.Diagnostic................................................................................... 400
20.8. Preclinical.Applications.of.pH-Sensitive.Liposomes.................................................. 400
20.8.1. Chagas.Disease................................................................................................... 400
20.8.2. Systemic.Cryptococcosis................................................................................... 401
20.8.3. Skin.Papilloma.................................................................................................... 402
20.8.4. Immune.Therapy/Vaccination.......................................................................... 402
20.8.4.1. Induction.of.Cytotoxic.T.Lymphocyte.(CTL).Responses............. 402
20.8.4.2. Induction.of.Cellular.Immunity...................................................... 403
20.8.5. Gene.Therapy...................................................................................................... 403
20.8.6. Salmonellosis....................................................................................................... 404
20.8.7. Complement.Activation..................................................................................... 405
20.9. Conclusions....................................................................................................................... 405
References..................................................................................................................................... 406
383
